A Phase 1, Open-label, Fixed Sequence Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs AL 335 (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 30 Nov 2016 Status changed from recruiting to completed.
- 22 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 22 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.